Pharvaris (PHVS) Stock Forecast, Price Target & Predictions
PHVS Stock Forecast
Pharvaris stock forecast is as follows: an average price target of $42.00 (represents a 123.05% upside from PHVS’s last price of $18.83) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
PHVS Price Target
PHVS Analyst Ratings
Buy
Pharvaris Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 14, 2024 | Justin Kim | Oppenheimer | $42.00 | $19.73 | 112.87% | 123.05% |
Apr 11, 2024 | Jonathan Wolleben | JMP Securities | $50.00 | $22.27 | 124.52% | 165.53% |
Sep 25, 2023 | Laura Chico | Wedbush | $27.00 | $20.67 | 30.62% | 43.39% |
Jan 11, 2023 | JMP Securities | $23.00 | $10.32 | 122.87% | 22.15% | |
Dec 09, 2022 | JMP Securities | $22.00 | $11.46 | 91.97% | 16.83% |
Pharvaris Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 2 |
Avg Price Target | - | $42.00 | $46.00 |
Last Closing Price | $18.83 | $18.83 | $18.83 |
Upside/Downside | -100.00% | 123.05% | 144.29% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Sep 06, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Jul 03, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Aug 15, 2023 | Morgan Stanley | Overweight | Upgrade | |
Feb 03, 2023 | SVB Leerink | Outperform | Outperform | Hold |
Jan 11, 2023 | JMP Securities | Market Outperform | Market Outperform | Hold |
Dec 09, 2022 | JMP Securities | Market Outperform | Market Outperform | Hold |
Pharvaris Financial Forecast
Pharvaris Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $7.60M | $2.38M | - | - | - | - | - | - | - | - | - |
High Forecast | $7.60M | $2.38M | - | - | - | - | - | - | - | - | - |
Low Forecast | $7.60M | $2.38M | - | - | - | - | - | - | - | - | - |
# Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Pharvaris EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Pharvaris Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-50.74M | $-52.79M | $-50.23M | $-37.93M | $-42.56M | $-41.48M | $-41.11M | $-40.37M | $-40.60M | $-35.56M | $-31.88M |
High Forecast | $-50.74M | $-52.79M | $-50.23M | $-37.93M | $-42.56M | $-41.48M | $-41.11M | $-39.80M | $-33.75M | $-35.56M | $-31.88M |
Low Forecast | $-50.74M | $-52.79M | $-50.23M | $-37.93M | $-42.56M | $-41.48M | $-41.11M | $-40.94M | $-53.25M | $-35.56M | $-31.88M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Pharvaris SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Pharvaris EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-0.94 | $-0.98 | $-0.93 | $-0.70 | $-0.79 | $-0.77 | $-0.76 | $-0.75 | $-0.75 | $-0.66 | $-0.59 |
High Forecast | $-0.94 | $-0.98 | $-0.93 | $-0.70 | $-0.79 | $-0.77 | $-0.76 | $-0.74 | $-0.63 | $-0.66 | $-0.59 |
Low Forecast | $-0.94 | $-0.98 | $-0.93 | $-0.70 | $-0.79 | $-0.77 | $-0.76 | $-0.76 | $-0.99 | $-0.66 | $-0.59 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Pharvaris Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
HOWL | Werewolf Therapeutics | $1.54 | $12.00 | 679.22% | Buy |
PEPG | PepGen | $4.03 | $29.50 | 632.01% | Buy |
MOLN | Molecular Partners | $5.31 | $29.00 | 446.14% | Buy |
PMVP | PMV Pharmaceuticals | $1.47 | $6.00 | 308.16% | Buy |
ANEB | Anebulo Pharmaceuticals | $1.62 | $6.00 | 270.37% | Buy |
ANTX | AN2 Therapeutics | $1.36 | $5.00 | 267.65% | Buy |
MLYS | Mineralys Therapeutics | $12.80 | $30.00 | 134.38% | Buy |
STOK | Stoke Therapeutics | $11.32 | $26.50 | 134.10% | Buy |
TYRA | Tyra Biosciences | $14.09 | $31.75 | 125.34% | Buy |
PHVS | Pharvaris | $18.83 | $42.00 | 123.05% | Buy |
DSGN | Design Therapeutics | $6.35 | $9.67 | 52.28% | Buy |
RZLT | Rezolute | $4.41 | $6.67 | 51.25% | Buy |
JANX | Janux Therapeutics | $56.14 | $70.25 | 25.13% | Buy |
IKNA | Ikena Oncology | $1.53 | $1.33 | -13.07% | Buy |